An oral vaccine reduced infection risk in a trial where people were deliberately exposed to high doses of norovirus, and ...

Vaxart Inc., in collaboration with researchers from multiple academic institutions, evaluated the VXA-G1.1-NN vaccine against ...

Vaxart's oral norovirus vaccine shows promise in mid-stage trials, reducing infections by 30%. Read more here.

Vaxart Inc (VXRT) reports significant revenue growth and clinical advancements, despite facing operational hurdles and NASDAQ ...

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced its business update and financial results for the first quarter of ...

In April 2025, Vaxart completed enrollment of all 60 participants for its Phase 1, open label, dose ranging clinical trial evaluating its second-generation oral norovirus vaccine constructs head ...

HilleVax reports Q1 2025 financials: $159.5 million in assets, reduced losses, and ongoing vaccine development for norovirus. HilleVax, Inc. announced its financial results for the first quarter ...

April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine ...

Topline data is expected in mid-2025, marking a key milestone in the development of a needle-free, shelf-stable pill vaccine to address norovirus, a leading global cause of acute gastroenteritis.